News & Events

Investors

Overview
News & Events
Presentations
Company Info
Analyst Coverage
Financial Info
Stock Data
SEC Filings
SEDAR+
Legend Removal
Governance

News & Events
Overview
Press Releases
IR Calendar
Email Alerts

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Apr 2, 2024 9:00am EDT

Recent Events View IR Calendar

Apr 23, 2024 1:00 pm PDT

Annual Meeting of Shareholders

Apr 9, 2024 10:30 am EDT – 10:55 am EDT

Email Alerts

Email Alerts
Contacts
RSS News Feed

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
105 Peach State Court, Suite A
Tyrone, GA 30290

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Back to the top

News & Events

Recent News View All News

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Lexaria Awarded New Patents

Recent Events View IR Calendar

Annual Meeting of Shareholders

LD Micro Invitational XIV

Email Alerts